A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
2018
Cancer
Daratumumab is a human CD38-directed monoclonal antibody indicated for the treatment of relapsed and refractory multiple myeloma (MM). A multicenter, open-label treatment protocol provided early access to daratumumab for patients who had progressive MM after they received ≥3 prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent or if they were refractory to both a proteasome inhibitor and an immunomodulatory agent. Patients received daratumumab 16 mg/kg
doi:10.1002/cncr.31706
pmid:30395359
pmcid:PMC6587745
fatcat:heopjvcz4fbk7chyy3bmsk7mra